IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 16, 2025, titled "Financial Results for the quarter and year ended 31st March 2025".
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals and Pharmaceuticals announced its Q4 and full-year FY25 results. In Q4 FY25, revenue grew 4.7% YoY to ₹527.8 Cr, EBITDA rose 17.1% to ₹67.5 Cr, and profit after tax (PAT) climbed 12.2% to ₹31.6 Cr, with EBITDA margin expanding by 141 basis points to 12.7%. For the full year FY25, however, revenue declined to ₹2,079.2 Cr from ₹2,132.8 Cr in FY24, while EBITDA fell to ₹224.6 Cr from ₹261.6 Cr and PAT dropped sharply to ₹101.0 Cr from ₹135.4 Cr, a 25% decline. FY25 EBITDA margin compressed by 140 basis points to 10.7%, and gross margin fell 160 bps to 33.8%, reflecting pricing pressure and competitive intensity. Operational highlights included commissioning of a new 10,800 MTPA Paracetamol unit, Clopidogrel capacity expansion, EDQM certifications, and entry into the China market for Ibuprofen exports.
Q4 shows a clear recovery with margin expansion and double-digit profit growth, but the full-year picture is weak, with revenue, EBITDA, and PAT all declining despite stable volumes. Investors may see the quarter as a sign of stabilisation, though the FY25 PAT decline of about 25% and margin compression could weigh on near-term sentiment until the new Paracetamol capacity starts contributing meaningfully.